2023 THRIVE Grant

Eligibility

Eligibility Details

Principal investigator(s) must hold an M.D., Ph.D., D.V.M., or equivalent degree.  Candidates for these degrees along with their Principal Investigator may apply. All candidates must have an accredited faculty, medical institution, or other research institute appointment and have the ability to conduct independent research with publications in established peer-reviewed medical and scientific journals. This funding opportunity is open internationally. Awardees must be willing to participate in the annual HESI THRIVE research forum – an opportunity to share results and build a network of experts.

Summary

Treatment related adverse impacts on patient quality of life are not unique to any one oncologic drug class or therapeutic approach and challenge our ability to support the best possible cancer patient outcomes. Despite the opportunity to do better, funding for research in this critical arena has been limited.

THRIVE offers funding for basic science, clinical, and translational research that enhances our ability to predict when and how adverse effects may occur in patients who have received cancer treatment and supports the development of approaches to avoid or lessen these effects. By providing researchers with both seed funding and access to critical networks, THRIVE will enhance the visibility of the patient need, the value of the research, and the reasons that larger funding entities might elect to incorporate these research streams into future funding priorities.

This unique program focuses on innovative cross-disciplinary research with defined impact for patients.  

THRIVE gives preference to those innovative research projects that engage both non-clinical AND clinical scientists in the research project design and/or implementation.  We believe that research at the translational boundary can make significant impact on the science and patients. This research will advance our:

• Fundamental understanding of cancer drug or therapy-related toxicity;
• Ability to identify and translate critical biomarkers of toxicity;
• Models (in vivo, in vitro, in silico) of pediatric or adult drug exposure that predict early or impending toxicities;
• Understanding of the role of protective co-therapies or modified exposure protocols on the onset of therapy-induced damage; and
• Identification of novel protective therapies or dosing-strategies

The THRIVE grant program is designed to provide seed funding to investigators for the testing of initial hypotheses and collecting of preliminary data to help secure long-term funding by the National Institutes of Health and/or other major granting institutions.

Pre-application deadlines

RSO internal deadline

Pre-application program deadline

Application deadlines

RSO detailed review deadline

RSO final internal review deadline

Program application deadline

NOTE: Consult your Faculty Associate Dean (Research) (ADR) regarding Faculty-specific deadlines and submission processes.

Principal Investigators: Complete a Research Management System (RMS) record, including a copy of your complete application, and submit this for approvals in RMS.

Approvals: The University of Calgary requires that all funding applications be approved prior to submission. Approval requires signatures via either RMS or the RFAA Trainee form, in the following order:

• Principal Investigator
• Department Head
• Faculty ADR/Dean
• Research Services (on behalf of the Vice-President Research)

Read the Meaning of Grant Signatures policy to understand what your approval means. Please see the agency guidelines for details about which signatures are required on your application, as it may differ from internal requirements.

Late submissions: Late submissions will only be accepted in cases of medical or family emergencies, or other exceptional circumstances. If you submit your RMS record to Research Services after the internal deadline has passed, you must secure additional approvals. Please read: Late Applications Process.

Application Process - Letter of Intent

1. The Principal Applicant will first have to set up a personal account on Proposal Central (if not already in the PC database)
2. Complete your Letter of Intent according to the Agency's Letter of Intent Guidelines
3. To initiate internal approvals, complete a Pre-Award/Letter of Intent record in RMS (https://my.rms.ucalgary.ca/), attach a PDF of your completed Letter of Intent (along with any additional required attachments), and submit for approvals from your department head and/or faculty Associate Dean (Research). NOTE: when submitting in RMS, please ensure that you allow time for academic approvals prior to the Research Services Office internal review deadline of 12:00pm MT, April 5, 2023.
4. Once these approvals are obtained, RMS will automatically forward the Application record to Research Services for institutional review and approval.
5. Research Services will review, provide feedback (by email) if necessary, and will provide the institutional approval. If digital or wet-ink signatures are required, we will provide the capping institutional signature and will advise when ready.
6. A fully approved Letter of Intent, including any supplementary documentation, must be submitted via ProposalCentral by April 10, 2023.

Applicants invited to submit full applications should email Chantal Lemire, Research Grants Officer (chantal.lemire@ucalgary.ca) for additional information on the next stage of this competition.